非小细胞肺癌患者血浆miR-21水平与化疗疗效的相关性  被引量:3

Correlation of plasma miR-21 level and chemotherapy efficacy in non-small cell lung cancer

在线阅读下载全文

作  者:胡军[1] 菅辉玲 李莉[1] 高丽霞[1] Hu Jun;Jian Huiling;Li Li;Gao Lixia(Department of Hematology and Oncology,Karamay Central Hospital,Xinjiang Karamay 834000,China)

机构地区:[1]克拉玛依市中心医院血液肿瘤科,新疆克拉玛依834000

出  处:《现代肿瘤医学》2020年第18期3155-3159,共5页Journal of Modern Oncology

基  金:克拉玛依市科技计划项目(编号:JK2015-3)。

摘  要:目的:探讨miRNA-21(miR-21)在非小细胞肺癌(NSCLC)患者血浆中的表达及治疗前后NSCLC患者血浆中miR-21水平与化疗药物疗效的相关性。方法:使用荧光定量PCR法检测并比较15例正常人和26例晚期NSCLC患者血浆中miR-21的表达差异;检测并比较晚期NSCLC患者化疗前后血浆中miR-21的变化水平。结果:NSCLC患者血浆中的miR-21表达水平显著高于正常人(P<0.01)。化疗后患者血浆中miR-21表达水平较化疗前存在差异(P<0.05)。miR-21在(SD+PD)组的表达量高于(CR+PR)组(P<0.05);而(CR+PR)组血浆miR-21的水平与正常对照组比较,无显著差异(P>0.05)。分析miR-21表达与NSCLC患者临床病理参数相关性,发现miR-21表达与患者临床特征无关。结论:血浆中miR-21的表达水平,对于NSCLC早期诊断及化疗药物治疗后评估患者疗效有较好地评判价值。Objective:To investigate the expression of miR-21 in plasma of patients with non-small cell lung cancer(NSCLC),and the relationship of miR-21 and chemotherapy efficacy in NSCLC before and after chemotherapy.Methods:The expression of miR-21 in plasma of 15 normal and 26 NSCLC was detected by RT-PCR.The expression change of miR-21 in NSCLC before and after chemotherapy was observed.Results:The expression of miR-21 in plasma of patients with NSCLC was significantly higher than that of normal subjects(P<0.01).The expression of miR-21 in plasma after chemotherapy was significantly different(P<0.05).The level of plasma miR-21 in the(SD+PD)group was significantly higher than the(CR+PR)group(P<0.05),which was similar to normal group(P>0.05).miR-21 expression was unrelated to the characteristics and pathological types of patients.Conclusion:The expression level of miR-21 can be used as a diagnosed and efficacy evaluating indicator when chemotherapy used in the treatment of NSCLC.

关 键 词:非小细胞肺癌 MIR-21 荧光定量 

分 类 号:R734.2[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象